Today's Hours: 8:00am - 6:00pm

Search

Filter Applied Clear All

Did You Mean:

Search Results

  • Book
    Choung Soo Kim, editor.
    Summary: This textbook summarizes the state of the art in the management of locally advanced and metastatic prostate cancer with the aim of providing the knowledge required for optimal treatment decision making in individual cases. Readers will find comprehensive coverage of the latest developments in surgery, radiotherapy, androgen deprivation therapy (ADT), chemotherapy, and immunotherapy. The role of the hormonal therapies abiraterone and enzalutamide and docetaxel-based chemotherapy in castration-resistant prostate cancer and hormone-sensitive metastatic disease is carefully evaluated. Among the other therapies discussed are LHRH agonists and antagonists, cabazitaxel, radium-223, and various novel agents still under clinical trials. The section on surgical approaches addresses, among other topics, the use of robot-assisted radical prostatectomy, pelvic lymphadenectomy, and the benefits of adjuvant and neoadjuvant therapy. The current role of external beam radiotherapy, alone or in combination with ADT and brachytherapy, for locally advanced disease is reviewed. Management of Advanced Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.

    Contents:
    Intro; Preface; Contents; Part I: Surgery for Advanced Prostate Cancer; 1: Natural History of High-Risk Prostate Cancer; 1.1 Introduction; 1.2 The Definition of High-Risk Prostate Cancer; 1.3 Risk Factors for High-Risk Prostate Cancer; 1.4 Natural History of High-Risk Prostate Cancer; 1.4.1 Localized or Locally Advanced High-Risk Prostate Cancer; 1.4.2 Hormone-Naïve Metastatic Prostate Cancer; 1.4.3 Castration-Resistant Prostate Cancer; 1.5 Summary; References; 2: Identifying the Best Candidate for Radical Prostatectomy in High-Risk Prostate Cancer; 2.1 Introduction 2.2 RP for High-Grade Cancer2.3 RP for T3/4 N0 M0 Disease; 2.4 RP for Node-Positive Disease; 2.5 The Efficacy of RP over External Beam Radiation Therapy (EBRT) with or Without ADT (Androgen Deprivation Therapy); 2.6 Safety of RP Compare to EBRT (with or Without ADT); 2.7 RP in Elderly Patients; 2.8 Recent Efforts for Identifying the Better Candidate for RP Among Patients with High-­Risk Prostate Cancer; 2.9 Summary; References; 3: Neoadjuvant Therapy Prior to Radical Prostatectomy; 3.1 Introduction; 3.2 Neoadjuvant Hormonal Therapy; 3.3 Neoadjuvant Chemotherapy with or Without ADT 3.4 Neoadjuvant Therapy Using Novel Medicines3.5 Summary; References; 4: Robot-Assisted Radical Prostatectomy for High-Risk Prostate Cancer; 4.1 Introduction; 4.2 What Is High-Risk PCa?; 4.3 RARP for High-Risk PCa; 4.3.1 Nerve Sparing in High-Risk PCa During RARP; 4.3.2 Lymph Node Dis
    section in High-Risk PCa During RARP; 4.3.3 Perioperative Morbidity During RARP; 4.4 Outcomes of RARP for High-­Risk PCa; 4.4.1 Oncologic Outcomes of RARP for High-Risk PCa; 4.4.2 Functional Outcomes of RARP for High-Risk PCa; References; 5: Pelvic Lymphadenectomy for High-Risk Prostate Cancer 5.1 Current Indication of Pelvic Lymphadenectomy in High-­Risk Prostate Cancer5.2 Extent of Pelvic Lymphadenectomy (Limited Vs. Extended); 5.3 Robotic Surgery and Pelvic Lymphadenectomy; 5.4 Clinical Outcome of Pelvic Lymphadenectomy; 5.5 Complication of Pelvic Lymphadenectomy; 5.6 Summary; References; 6: Adjuvant Therapy in Locally Advanced Prostate Cancer; 6.1 Introduction; 6.2 Definition; 6.3 General Guidelines by NCCN; 6.4 RP for Locally Advanced PCa; 6.5 RT in Locally Advanced PCa; 6.6 Multimodality Treatment in Locally Advanced PCa; 6.7 Adjuvant Postoperative RT 6.8 Adjuvant HT6.9 Adjuvant Chemotherapy; 6.10 Summary; References; 7: Role of Radical Prostatectomy in the Management of Metastatic Prostate Cancer; 7.1 Classic Role of Radical Prostatectomy for Palliative Local Symptom Control; 7.2 Feasibility of Radical Prostatectomy in Metastatic Prostate Cancer; 7.3 Possible Rationale for Cytoreductive Radical Prostatectomy in Metastatic Prostate Cancer; 7.4 Indirect Evidence Supporting the Effectiveness of Cytoreductive Radical Prostatectomy
    Digital Access Springer 2018